Patent application number | Description | Published |
20080199540 | Orally-administrable compositions comprising stable amorphous calcium carbonate - The present invention provides orally-administrable compositions comprising stable amorphous calcium carbonate (ACC). The compositions are preferably prepared as solid dosage forms such as tablets, capsules and powders. The present invention further provides methods for supplementing oral calcium intake in subjects and as well as methods for treating osteoporosis, osteomalacia and related diseases. | 08-21-2008 |
20100012581 | DENITRIFICATION TREATMENT SYSTEM AND METHOD - A two-stage treatment process, for the treatment of nitrate rich water, particularly aquaculture pond water, wherein in the first stage a degassing chamber is used for removing dissolved oxygen from a stream of water flowing out of the aquaculture system, and in the second stage the stream of water obtained from said degassing chamber is flown into a denitrifying biofilter comprising a biofilter media which functions as a biological growth media and as a carbon source, wherein said denitrifying biofilter is capable of biologically reducing both nitrate and nitrite compounds into nitrogen gas. | 01-21-2010 |
20100098774 | COMPOSITION COMPRISING CRUSTACEAN GASTROLITH COMPONENTS AND ITS USE - Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consists of chitin and polypeptide. The formulation is efficient in treating various pathological conditions, including proliferative diseases, neurological disorders, and musculoskeletal disorders. | 04-22-2010 |
20100221362 | STABLE AMORPHOUS CALCIUM CARBONATE COMPRISING SYNTHETIC PHOSPHORYLATED PEPTIDES - Provided are compositions containing amorphous calcium carbonate (ACC), and at least one phosphorylated peptide which stabilizes the amorphous form of said calcium carbonate. Particularly, the peptide can be selected from crustacean proteins, also provided by the invention, namely GAP65, GAP22, GAP21, and GAP12 (also indicated herein as GAP10). The compositions are useful in pharmaceutical and nutraceutical formulations. | 09-02-2010 |
20100310677 | STABLE AMORPHOUS CALCIUM CARBONATE COMPRISING PHOSPHORYLATED AMINO ACIDS - Provided are compositions containing amorphous calcium carbonate (ACC), and at least one phosphorylated amino acid which stabilizes the amorphous form of said calcium carbonate. The compositions are useful in pharmaceutical and nutraceutical formulations. | 12-09-2010 |
20110010784 | INSULIN-LIKE GENE OF PRAWNS AND USES THEREOF - Nucleic acid molecules encoding an insulin-like factor of the androgenic gland of the freshwater prawn | 01-13-2011 |
20120073508 | INSULIN-LIKE GENE IN PRAWNS AND USES THEREOF - The present invention relates to a nucleic acid molecule encoding an insulin-like factor of the androgenic gland of the freshwater prawn | 03-29-2012 |
20130122117 | COMPOSITION COMPRISING CRUSTACEAN GASTROLITH COMPONENTS AND ITS USE - Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consists of chitin and polypeptide. The formulation is efficient in treating various pathological conditions, including proliferative diseases, neurological disorders, and musculoskeletal disorders. | 05-16-2013 |
20150056306 | AMORPHOUS CALCIUM CARBONATE FOR THE TREATMENT OF CALCIUM MALABSORPTION AND METABOLIC BONE DISORDERS - Provided are methods for treating calcium malabsorption and conditions associated with calcium malabsorption, employing the administration of a composition containing stable amorphous calcium carbonate. Further provided are methods for increasing bone mineral density in a bone metabolism associated disorders, diseases or conditions, employing the administration of said composition in combination with a bone resorption inhibitor. | 02-26-2015 |